Drug Type Bispecific antibody |
Synonyms |
Target |
Action inhibitors, modulators |
Mechanism NCR3 inhibitors(natural cytotoxicity triggering receptor 3 inhibitors), ROR1 modulators(Inactive tyrosine-protein kinase transmembrane receptor ROR1 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 08 Nov 2023 |